GlaxoSmithKline, which filled the seat of CEO-bound Emma Walmsley on Thursday, isn’t the only Big Pharma to tap a new consumer chief this week.
On Friday, rival Sanofi announced it had appointed Alan Main to lead its OTC efforts, which will take the form of a newly created consumer health global business unit.
It’s a poach job by new Sanofi CEO Olivier Brandicourt, who recruited Main from his former employer, Bayer. At the German drugmaker, Main served as global president of medical care, but he has plenty of consumer experience from his pre-Bayer days at Roche Consumer Health, a business Bayer picked up in 2004.
Now, he’ll be tasked with leading a newly bulked-up business in an increasingly competitive space. Sanofi is currently working to close an asset swap for Boehringer Ingelheim’s consumer portfolio–for which it traded away its animal health offerings–and it expects to do so by the end of this year. Once it does, it’ll become a leader in the OTC field, it figures–meeting one of the key goals it laid out in its “roadmap 2020.”
Of course, Sanofi isn’t the only player fighting to gain ground in the consumer health arena. GlaxoSmithKline, which took the lead after starting up a JV with Novartis early last year, intends to keep the top spot, and it Thursday announced that Novartis vet Brian McNamara would be leading that charge as head of the venture.
Bayer, too, has said it’s gunning for the worldwide No. 1 position in the OTC market, though lately it’s focused its energies elsewhere. Earlier this month, it agreed to shell out $66 billion on agricultural giant Monsanto, a deal some industry watchers worry will hurt its pharma ambitions.
By Carly Helfand
Source: Fierce Pharma
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”
